European Journal of Clinical Investigation最新文献

{"title":"Extracellular matrix mechanical cues (dys)regulate metabolic redox homeostasis due to impaired autophagic flux","authors":"Heloísa Gerardo,&nbsp;Tânia Lourenço,&nbsp;Júlio Torres,&nbsp;Manuela Ferreira,&nbsp;Célia Aveleira,&nbsp;Susana Simões,&nbsp;Lino Ferreira,&nbsp;Cláudia Cavadas,&nbsp;Paulo J. Oliveira,&nbsp;José Teixeira,&nbsp;Mário Grãos","doi":"10.1111/eci.70051","DOIUrl":"10.1111/eci.70051","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Extracellular matrix (ECM) stiffness is increasingly recognized as a critical regulator of cellular behaviour, governing processes such as proliferation, differentiation, and metabolism. Neurodegenerative diseases are characterized by mitochondrial dysfunction, oxidative stress, impaired autophagy, and progressive softening of the brain tissue, yet research into how mechanical cues influence cellular metabolism in this context remains scarce.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Materials and Methods</h3>\u0000 \u0000 <p>In this study, we evaluated the long-term effects of brain-compliant, soft ECM on mitochondrial bioenergetics, redox balance, and autophagic capacity in human neuroblastoma (SH-SY5Y) and mouse hippocampal (HT22) cell lines, as well as primary mouse neurons.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>We observed that prolonged exposure to soft ECM does not impact cell proliferative capacity of neuronal cells but results in mitochondrial bioenergetic dysfunction, redox imbalance, and disrupted autophagic flux. These findings were consistently validated across both human and mouse neuronal cells. Our data indicate a decreased maximal autophagic capacity in cells exposed to long-term soft ECM, potentially due to an imbalance in autophagosome formation and degradation, as demonstrated by decreased LC3 II levels following chloroquine-induced autophagic flux inhibition. This impairment in autophagy was coupled with increased cellular oxidative stress, further indicating metabolic alterations.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>These findings emphasize the critical role of ECM stiffness in regulating neuronal cell metabolism and suggest that prolonged exposure to soft ECM may mimic key aspects of neurodegenerative disease pathology, thereby enhancing the physiological relevance of in vitro models. This study underscores the necessity for further research into ECM mechanics as a contributing factor in neurodegenerative disease progression and as a potential target for therapeutic strategies.</p>\u0000 </section>\u0000 </div>","PeriodicalId":12013,"journal":{"name":"European Journal of Clinical Investigation","volume":"55 9","pages":""},"PeriodicalIF":3.6,"publicationDate":"2025-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143964911","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cancer and cardiovascular diseases: A deadly combination","authors":"Aldo Bonaventura,&nbsp;Luca Liberale,&nbsp;Federico Carbone,&nbsp;Fabrizio Montecucco","doi":"10.1111/eci.70060","DOIUrl":"10.1111/eci.70060","url":null,"abstract":"","PeriodicalId":12013,"journal":{"name":"European Journal of Clinical Investigation","volume":"55 7","pages":""},"PeriodicalIF":4.4,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143959916","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of 4-month treatment with glycocalyx dietary supplement on endothelial glycocalyx and vascular function after COVID-19 infection","authors":"George Pavlidis,&nbsp;Aikaterini Kountouri,&nbsp;Konstantinos Katogiannis,&nbsp;John Thymis,&nbsp;Panagiota Efstathia Nikolaou,&nbsp;Christina Chania,&nbsp;John Karalis,&nbsp;Gabriella Kostelli,&nbsp;Eleni Michalopoulou,&nbsp;Eleni Katsanaki,&nbsp;John Parissis,&nbsp;Hans Vink,&nbsp;Robert Long,&nbsp;Sotirios Tsiodras,&nbsp;Vaia Lambadiari,&nbsp;Ignatios Ikonomidis","doi":"10.1111/eci.70058","DOIUrl":"10.1111/eci.70058","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Coronavirus disease 2019 (COVID-19) has been associated with impaired endothelial and vascular function. We investigated whether intervention with glycocalyx dietary supplement (GDS), containing glucosamine sulfate and fucoidan, improves endothelial glycocalyx and vascular function after COVID-19 infection.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Fifty-seven convalescent patients 14 days after mild-to-moderate COVID-19 infection managed in an outpatient setting were randomized to receive GDS (<i>n</i> = 29) or placebo (<i>n</i> = 28) for 4 consecutive months. We measured at baseline and at 4 months: (a) perfused boundary region (PBR) of the sublingual microvessels with a diameter range of 4–25 μm, as a marker of endothelial glycocalyx integrity, (b) pulse wave velocity and augmentation index, (c) coronary flow reserve using Doppler echocardiography, and (d) malondialdehyde and protein carbonyls as oxidative stress markers.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Four months after treatment, patients who received GDS showed a greater reduction in PBR 4–25 μm (−6.8% vs. −1.3%), pulse wave velocity (−13.2% vs. −3%), augmentation index (−28.5% vs. −2.5%), malondialdehyde (−26% vs. −2.9%), protein carbonyls (−31.3% vs. −1%) and a greater increase in coronary flow reserve (12.9% vs. 1.6%) compared to placebo (<i>p</i> &lt; .05). In the GDS group, the reduction in PBR 4–25 μm was associated with the corresponding decrease in pulse wave velocity (<i>r</i> = .31, <i>p</i> = .047), malondialdehyde, and protein carbonyls, as well as with the increase in coronary flow reserve (<i>r</i> = −.59, <i>p</i> = .008) at follow-up. Post-treatment, none of the patients under GDS reported post-COVID symptoms compared to 21.4% of the patients under placebo.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Four-month treatment with GDS may improve endothelial glycocalyx and vascular function after COVID-19 infection.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Clinical Trial Registration</h3>\u0000 \u0000 <p>URL: https://www.clinicaltrials.gov. Unique identifier: NCT05185934.</p>\u0000 </section>\u0000 </div>","PeriodicalId":12013,"journal":{"name":"European Journal of Clinical Investigation","volume":"55 7","pages":""},"PeriodicalIF":4.4,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/eci.70058","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143991516","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The evolving role of positron emission tomography in precision prostate cancer biopsy","authors":"Alessio Imperiale,&nbsp;Valentina Berti,&nbsp;Roberto Luigi Cazzato,&nbsp;Darejan Mamulashvili Bessac,&nbsp;Alice Ressault,&nbsp;Luca Vaggelli,&nbsp;Mehdi Helali,&nbsp;Camilo Garcia,&nbsp;Hervé Lang,&nbsp;Desirée Deandreis,&nbsp;Luc Mertz,&nbsp;Afshin Gangi","doi":"10.1111/eci.70062","DOIUrl":"10.1111/eci.70062","url":null,"abstract":"<p>Prostate cancer is one of the most common cancers among men, and accurate detection and diagnosis are crucial for effective treatment planning. Diagnostic prostate biopsy plays a pivotal role in the detection and characterization of prostate cancer. Recent advancements in molecular imaging, particularly with Positron Emission Tomography (PET) using radiolabelled Prostate-Specific Membrane Antigen (PSMA) tracers, have shown significant improvements in enhancing prostate cancer detection. PSMA PET, when combined with magnetic resonance imaging (MRI) in hybrid PET/MRI systems, provides improved sensitivity and specificity, enabling more precise localization of clinically significant prostate cancer (csPCa) lesions. This narrative review explores the evolving role of PET/CT and PET/MRI-guided prostate biopsy. We examine the integration of PET with MRI for the detection of prostate cancer, highlighting key studies that have demonstrated improved diagnostic outcomes. Additionally, we discuss the current limitations, including the high costs and longer scan times associated with PET/MRI, as well as the challenges in data interpretation. The review also considers emerging technologies, such as promising molecular probes for prostate PET imaging, such as gastrin-releasing peptide receptor (GRPR) and fibroblast activation protein inhibitor (FAPI). Finally, the present work provides the clinician with a comprehensive yet concise up-to-date review of the literature to easily evaluate the possibilities currently offered by hybrid imaging technologies of personalized imaging-guided biopsy for prostate cancer patients.</p>","PeriodicalId":12013,"journal":{"name":"European Journal of Clinical Investigation","volume":"55 8","pages":""},"PeriodicalIF":4.4,"publicationDate":"2025-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/eci.70062","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143988284","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"SGLT-2 inhibitors for cardiac amyloidosis: Hype or hope?","authors":"Flavio Tangianu,&nbsp;Eleonora Nicolini,&nbsp;Francesco Dentali,&nbsp;Aldo Bonaventura","doi":"10.1111/eci.70063","DOIUrl":"10.1111/eci.70063","url":null,"abstract":"&lt;p&gt;Cardiac amyloidosis (CA), resulting either from misfolded immunoglobulin light-chain (light-chain amyloidosis [AL]) or transthyretin (transthyretin amyloidosis [ATTR]) proteins, is responsible for a progressive impairment of cardiac function causing heart failure (HF).&lt;span&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt; Despite the approval of disease-modifying treatments (DMTs) for ATTR-CA (tafamidis and acoramidis) and other drugs in the pipeline,&lt;span&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/span&gt; a number of patients cannot access currently approved DMTs due to economic reasons, advanced stage of disease, or specific aetiology (i.e., AL), and supportive care remains the cornerstone for HF management.&lt;span&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/span&gt; Furthermore, patients with CA were excluded from large clinical trials testing guideline-directed medical treatments (GDMTs) in patients with HF. A retrospective analysis of ATTR-CA patients, however, showed benefits of low-dose β-blockers (in those with left ventricular ejection fraction [LVEF] ≤40%) and mineralocorticoid receptor antagonists (MRAs) on all-cause mortality reduction (in all patients, and particularly in those with LVEF &gt;40%).&lt;span&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/span&gt; Similarly, hitherto sparse evidence reported positive effects on the reduction of HF hospitalization as well as on cardiovascular (CV) and all-cause mortality for sodium-glucose cotransporter-2 (SGLT-2) inhibitors.&lt;span&gt;&lt;sup&gt;5, 6&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;Karakasis et al. recently reported in the &lt;i&gt;European Journal of Clinical Investigation&lt;/i&gt; the results of a systematic review and meta-analysis about the use of SGLT-2 inhibitors in patients with CA.&lt;span&gt;&lt;sup&gt;7&lt;/sup&gt;&lt;/span&gt; By considering 9766 participants from five observational studies, SGLT-2 inhibitors reduced all-cause and CV mortality, major adverse CV events, and hospitalizations for HF and were associated with a reduced occurrence of cardiac arrhythmias (atrial fibrillation, ventricular tachycardia and cardiac arrest).&lt;span&gt;&lt;sup&gt;7&lt;/sup&gt;&lt;/span&gt; Irrespective of a number of limitations deriving from the observational design of the studies considered, which were correctly acknowledged by the Authors, this meta-analysis clearly suggests that SGLT-2 inhibitors are effective drugs that can improve the prognosis of CA patients.&lt;/p&gt;&lt;p&gt;Patients with CA present with a peculiar impairment in hemodynamics. Indeed, they show increased pulmonary capillary wedge pressure (PCWP), right atrial pressure (RAP) and mean arterial pulmonary artery pressure (mPAP) as well as reduced cardiac index (CI) and stroke volume index (SVI) at rest.&lt;span&gt;&lt;sup&gt;8&lt;/sup&gt;&lt;/span&gt; Importantly, a reduced CI was found as the strongest factor associated with a combination of cardiac transplantation, need for left ventricle assist device, or all-cause mortality and HF hospitalization.&lt;span&gt;&lt;sup&gt;8&lt;/sup&gt;&lt;/span&gt; During exercise, a drastic worsening of pulmonary hypertension is observed in these patients along with a net reduction in pulmonary arterial compliance and an unchanged pulmonary vascular r","PeriodicalId":12013,"journal":{"name":"European Journal of Clinical Investigation","volume":"55 11","pages":""},"PeriodicalIF":3.6,"publicationDate":"2025-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/eci.70063","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143984564","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The contribution of prolactin in the occurrence of premature cardiovascular disease predominantly through modulating the inflammatory cascade","authors":"Lisa Kamperdijk,&nbsp;Nikol Shkarpa,&nbsp;Marcel Th. B. Twickler","doi":"10.1111/eci.70042","DOIUrl":"10.1111/eci.70042","url":null,"abstract":"<p>Cardiovascular disease, mainly coronary atherothrombosis, is an essential contributor to all-cause mortality, accounting for approximately 30% of all global deaths. Imbalances in hormone profiles may play a role in the evolution of atherothrombosis. In the last decade, our clinical research focused on the hormone prolactin (PRL) and its contribution to premature cardiovascular disease. In this narrative review, we aimed to give current insights into how PRL could modulate the inflammatory cascade within the microenvironment of the atherosclerotic plaque, which could lead to increased cardiovascular morbidity and mortality.</p>","PeriodicalId":12013,"journal":{"name":"European Journal of Clinical Investigation","volume":"55 8","pages":""},"PeriodicalIF":4.4,"publicationDate":"2025-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143998936","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prediction of major outcomes in patients with malignant hypertension using machine learning: A report from the West Birmingham malignant hypertension registry","authors":"Antonios A. Argyris,&nbsp;Hironori Ishiguchi,&nbsp;Yang Chen,&nbsp;Yalin Zheng,&nbsp;Alena Shantsila,&nbsp;Eduard Shantsila,&nbsp;D. Gareth Beevers,&nbsp;Gregory Y. H. Lip","doi":"10.1111/eci.70052","DOIUrl":"10.1111/eci.70052","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Malignant hypertension (MHT) is a rare, yet severe condition with high morbidity and mortality. We aimed to assess the potential of machine learning (ML) algorithms in forecasting prognostic outcomes in MHT patients.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Data from the West Birmingham MHT Registry were used. We evaluated the efficacy of 9 ML algorithms, CatBoost, Decision Tree (DT), Light-Gradient Boosting Machine (LightGBM), K-Nearest Neighbours (KNN), Logistic Regression (LR), Multi-Layer Perceptron (MLP), Random Forest (RF), Support Vector Machine (SVM) and XGBoost in predicting a composite outcome of all-cause mortality/dialysis. Evaluation metrics included the area under the receiver operating characteristic curve (AUC) and F1 score. SHapley Additive exPlanations values were employed to quantify the importance of each feature.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The cohort comprised 385 individuals with MHT (mean age 48 ± 13 years, 66% male). During a median follow-up of 11 (interquartile range: 3–18) years, 282 patients (73%) experienced the composite outcome. Among 24 demographic and clinical variables, 16 were selected into the ML models. The SVM, LR, and MLP models exhibited robust predictive performance, achieving AUCs of .81 (95% CI: .70–.90), .82 (95% CI: .71–.92) and .81 (95% CI: .71–.90), respectively. Furthermore, these models demonstrated high F1 scores (SVM: .75, LR: .80. MLP: .75). Age, smoking, follow-up systolic blood pressure, and baseline creatinine were commonly identified as primary prognostic features in both SVM and LR models.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>The application of ML algorithms facilitates effective prediction of prognostic outcomes in MHT patients, illustrating their potential utility in clinical decision-making through more targeted risk stratification and individualised patient care.</p>\u0000 </section>\u0000 </div>","PeriodicalId":12013,"journal":{"name":"European Journal of Clinical Investigation","volume":"55 9","pages":""},"PeriodicalIF":3.6,"publicationDate":"2025-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/eci.70052","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143981234","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Phenotypic patterns of metabolic dysfunction-associated steatotic liver disease in type 2 diabetes: The impact of insulin","authors":"Queralt Martín-Saladich,&nbsp;Rafael Simó,&nbsp;Andreea Ciudin,&nbsp;Julia Baguña,&nbsp;Clara Ramirez-Serra,&nbsp;Santiago Aguadé-Bruix,&nbsp;Albert Roque,&nbsp;Maria N. Pizzi,&nbsp;Hug Cuéllar,&nbsp;Nuria Roson-Gradaille,&nbsp;Miguel A. González Ballester,&nbsp;Juan M. Pericàs,&nbsp;José Raul Herance","doi":"10.1111/eci.70050","DOIUrl":"10.1111/eci.70050","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Metabolic dysfunction-associated steatotic liver disease (MASLD) often leads to hepatic insulin resistance (IR), yet its link to liver-specific insulin-mediated glucose uptake (IGLU) in type 2 diabetes (T2D) remains unclear. We aimed to explore this MASLD-T2D relationship, addressing organ-specific IR for personalized management and risk prevention.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This cross-sectional study included 41 T2D participants enrolled in a clinical trial (NCT02248311) undergoing biochemical analyses, anthropometric measurements and [¹⁸F]FDG-PET/CT imaging before and after hyperinsulinemic euglycemic clamp (HEC).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Findings</h3>\u0000 \u0000 <p>Two MASLD-T2D phenotypes were identified according to their IGLU patterns, that is, with low (HepGluc[+], <i>n</i> = 21) and with high (HepGluc[−], <i>n</i> = 20) hepatic response to insulin. HepGluc[+] participants exhibited increased systemic IR (HOMA-IR, <i>p</i> = .012), inflammation (interleukin 6, <i>p</i> = .005); alanine and aspartate aminotransferase ALT, AST (<i>p</i> = .015 and <i>p</i> = .007); gamma-glutamyl transferase GGT (<i>p</i> = .019) and steatosis markers (liver volume, <i>p</i> = .006); NAFLD liver fat score, <i>p</i> = .0017; hepatic steatosis index, <i>p</i> = .02; fatty liver index, <i>p</i> = .008; liver stiffness measurements (LSM) (<i>p</i> = .049). No statistical differences in serum-based liver fibrosis scores were shown. To identify MASLD-T2D phenotypes in a friendly manner, the MASLD-T2D score based on support vector machines was developed using AST, ALT and GGT (AUC = .83), as well as with MASLD indices including LSM and NAFLD liver fat score (AUC = .90).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Implications</h3>\u0000 \u0000 <p>Two new MASLD-T2D phenotypes have been identified, HepGluc[+] and HepGluc[−], according to IGLU patterns, with HepGluc[+] being more deleterious due to higher systemic IR, steatosis and inflammation. Phenotypes can be identified using a new function, the MASLD-T2D score.</p>\u0000 </section>\u0000 </div>","PeriodicalId":12013,"journal":{"name":"European Journal of Clinical Investigation","volume":"55 9","pages":""},"PeriodicalIF":3.6,"publicationDate":"2025-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/eci.70050","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144004570","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to ‘Association Between Exposure to Air Pollution and Blood Lipids in the General Population of Spain’","authors":"","doi":"10.1111/eci.70047","DOIUrl":"10.1111/eci.70047","url":null,"abstract":"<p>Valdés S, Doulatram-Gamgaram V, Maldonado-Araque C, García-Escobar E, García-Serrano S, Oualla-Bachiri W, García-Vivanco M, Garrido JL, Gil V, Martín-Llorente F, Calle-Pascual A, Castaño L, Delgado E, Menéndez E, Franch-Nadal J, Gaztambide S, Girbés J, Chaves FJ, Galán-García JL, Aguilera-Venegas G, Vallvé JC, Amigó N, Guardiola M, Ribalta J, Rojo-Martínez G. Association between exposure to air pollution and blood lipids in the general population of Spain. <i>Eur J Clin Invest</i>. 2024;54(2):e14101.</p><p>In paragraph 4 of the ‘Funding Information’ section, the text ‘European Regional Development Fund (ERDF) “A way to build Europe”’, was incorrect. This should have read ‘funded by ISCIII and cofounded by the European Union’.</p><p>We apologize for this error.</p>","PeriodicalId":12013,"journal":{"name":"European Journal of Clinical Investigation","volume":"55 7","pages":""},"PeriodicalIF":4.4,"publicationDate":"2025-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/eci.70047","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144063187","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of RNA interference therapeutics in transthyretin cardiac amyloidosis: A systematic review and meta-analysis","authors":"Shehroze Tabassum,&nbsp;Farhan Naeem,&nbsp;Mohamed Saad Rakab,&nbsp;Abdul Mannan Khan Minhas,&nbsp;Ramesh Daggubati,&nbsp;M. Chadi Alraies","doi":"10.1111/eci.70049","DOIUrl":"10.1111/eci.70049","url":null,"abstract":"<p>RNAi therapeutics represent a promising advancement in the treatment of ATTR-CM, offering significant benefits over placebo. It demonstrated substantial improvements in survival, functional capacity, and quality of life, alongside a marked reduction in BNP levels and GLS—critical biomarkers of disease progression. These findings underscore the potential of RNAi therapy to alter the disease trajectory and improve patient outcomes.\u0000 <figure>\u0000 <div><picture>\u0000 <source></source></picture><p></p>\u0000 </div>\u0000 </figure></p>","PeriodicalId":12013,"journal":{"name":"European Journal of Clinical Investigation","volume":"55 7","pages":""},"PeriodicalIF":4.4,"publicationDate":"2025-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144063188","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}